LYTENAVA
NDC 82491-025 · Outlook Therapeutics, Inc.
Generic namebevacizumab-vikg
Dosage formINJECTION
RouteINTRAVITREAL
Active ingredient(s)BEVACIZUMAB
Strength1.25 mg/1
Pharmacologic classVascular Endothelial Growth Factor Inhibitor [EPC], Vascular Endothelial Growth Factor Inhibitors [MoA], Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]
Marketing categoryBLA
Packages
82491-025-10 — 1 VIAL, GLASS in 1 CARTON (82491-025-10) / 1 INJECTION in 1 VIAL, GLASS
Related Codes
Same active ingredient
FDA lists these products with the same active ingredient.
0069-0315 — bevacizumab-bvzr, 0069-0342 — bevacizumab-bvzr, 50242-060 — bevacizumab, 50242-061 — bevacizumab, 55513-206 — bevacizumab-awwb, 55513-207 — bevacizumab-awwb, 70121-1754 — bevacizumab-maly, 70121-1755 — bevacizumab-maly, 72606-011 — bevacizumab-adcd, 72606-012 — bevacizumab-adcd, 83257-009 — bevacizumab-nwgd, 83257-010 — bevacizumab-nwgd